USA – Meliora Therapeutics, a Menlo Park,Ca-based biotech company, raised $11M in Seed funding.
The round was led by HOF Capital, with participation from ZhenFund, Obvious Ventures, Village Global, BrightEdge, Pebblebed, Axial, Olive Capital, Michael Polansky, and Wes Sterman, and others.The company intends to use the funds to expand its computational platform, which includes building a proprietary data moat and selecting mischaracterized scaffolds as strong starting points for its therapeutic programs, extend the team, operations, and build industry partnerships.Led by CEO David Li, Meliora Therapeutics is a cancer drug developer advancing “molecular fingerprints” for tens of thousands of compounds in order to build an inference engine that identifies risk-adjusted small molecule compound and target mechanism of action (MOA) pairs. The computational platform allows companies to identify the mechanism of action in small molecule compounds, and uncover mischaracterized compounds in the process.The founding team includes Li, Jason Sheltzer, Ph.D., Scientific Co-Founder and Joan Smith, Technical Co-Founder.29/09/2022
